You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

man on ladder

SHINGRIX herpes zoster vaccine [recombinant, adjuvanted]

If you can prevent shingles suffering, why wouldn't you?

Date of preparation: September 2023 PM-IE-SGX-WCNT-230004

Prescribing information link

Quick links

Therapy area:
 

Oncology

Respiratory

Vaccines

HIV

See all therapy areas

Resources:
 

Sample and training devices

Patient resources

Healthcare professional resources

See all resources

Live and On-Demand Events:

 

Join your peers and healthcare experts at live events run by GSK. Catch up on Asthma, COPD and Vaccines event recordings anytime from the comfort of your own office

 

See all events

Trelegy▼Ellipta Logo

‌Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol [as trifenatate])

Learn more

Nucala Logo

Nucala (mepolizumab)

Learn more

Zejula Logo

Zejula (Niraparib)

Learn more

Shingrix Logo

Shingrix (herpes zoster vaccine recombinant, adjuvanted)

Learn more

More resources

Zejula▼ (Niraparib)

Zejula (Niraparib) patient booklet available to order online

This Zejula patient booklet has been developed to provide information on some of the questions patients prescribed Zejula may have and helps to support them on their treatment journey.1

Order today

Prescribing information

Shingrix▼(Herpes zoster vaccine recombinant, adjuvanted)

If you can prevent Shingles suffering, why wouldn't you?2

Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in adults 50 years of age or older and in adults 18 years of age or older at increased risk of HZ.2

Learn more

Prescribing information

Dovato(dolutegravir/lamivudine)

Dovato (dolutegravir/lamivudine)

Virological suppression is the first step to achieving HIV+Healthy. For your patients living with HIV, learn more about how Dovato could be a part of their healthy future.3,4

 

Learn More

Prescribing information

Trelegy▼Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Using dual therapy or triple therapy for your patients?

The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI).5

Explore the IMPACT data

Prescribing information

Get more from GSKpro

Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines

Register in 2 minutes

Abbreviations

FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References
  1. Zejula Summary of Product Characteristics. Available from: www.medicines.ie. Last accessed April 2022
  2. SHINGRIX Summary of Product Characteristics. Available from: www.medicines.ie last access April 2022
  3. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  4. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
  5. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-NA-WCNT-220009 Date of Preparation: August 2023